CF PharmTech Raises ￥360M in Series F Funding

According to VCBeat, after a ￥630 million Series E financing in January, CF PharmTech, Inc. ("CF PharmTech") raised 360 million yuan in Series F funding recently, led by BioTrack Capital and CICC Capital's sub-fund CICC Qichen, with participation with CICC Qide SAIC Capital, Jinpu Merger and Acquisition Fund, and Wosheng Capital. Existing shareholders Passion Capital and Yuanming Capital continued to inject money into this round. CEC Capital served as the exclusive financial adviser to CF PharmTech.

Founded in 2007 in Suzhou, Jiangsu Province, CF PharmTech is a specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effective management care for their respiratory diseases. The company has established an R&D base and production facilities of inhalation products for the global high-end market.

Respiratory diseases have become a common kind of diseases in the world. In China, the number of patients with asthma, COPD and rhinitis is expected to exceed 300 million, and it is still growing rapidly.

In order to realize the reasonable price and reliable quality of products for Chinese people, CF PharmTech has gathered a senior team engaged in the development of respiratory drug delivery technology for a long time, and built the backbone of China's professional inhaled drug R&D and production. The company is making continuous efforts for developing new drugs based on its existing pipeline.

Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. The company focuses on innovative biotech companies, innovative MedTech companies, and innovative business models in healthcare.

SAIC Capital is a venture capital firm specializing in direct and fund of funds investments, with registered capital of 4 billion yuan. The company is a domestic professional investment management platform and a third-party asset management platform of SAIC Group.